Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Calgary

$25,000.00

Exploring the utility of mass spectrometric data for enhancing protein structure modeling

FY 2009-10

Summary
The well-established paradigm of drug discovery involves targeting a specific protein with a specific compound to alter its function. Most often, these proteins are enzymes or receptors that can be linked in some fashion to disease processes. But as we unravel biological matter at the molecular level, we begin to see that a great many protein functions are integrated in very complex molecular machines. Our research program begins with this idea: if we can develop new technologies for understanding the assembly and function of these machines at a high resolution, a new therapeutic paradigm more sophisticated than the "one-protein, one-drug" approach could be developed. Our research addresses the development, testing and evolution of technology for such purposes. Our goals involve the development of mass spectrometry for the analysis of protein structure, assembly and dynamics, but we realize that this powerful technology will be insufficient for generating the degree of resolution we need to understand function. Computational methods will be developed to enhance the value of the data generated by mass spectrometry. With the successful development and maturation of this "merged" approach, we hope initiate new projects in therapeutics development focused on cancer treatment.
Program
Discovery Grants Program - Individual
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
298351-2008
Name nom
Schriemer, David
Department département
Biochemistry and Molecular Biology
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2008
Award amount
25000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
26
Committee name en
Anal. & Phys. Chemistry
Committee name fr
Chimie analytique et physique
Area of application code
515
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Instrumentation technology
Area of application fr
Technologie de l'instrumentation
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
2
Nb partie
2
Application title
Exploring the utility of mass spectrometric data for enhancing protein structure modeling
Keyword
NA
Application summary
The well-established paradigm of drug discovery involves targeting a specific protein with a specific compound to alter its function. Most often, these proteins are enzymes or receptors that can be linked in some fashion to disease processes. But as we unravel biological matter at the molecular level, we begin to see that a great many protein functions are integrated in very complex molecular machines. Our research program begins with this idea: if we can develop new technologies for understanding the assembly and function of these machines at a high resolution, a new therapeutic paradigm more sophisticated than the "one-protein, one-drug" approach could be developed. Our research addresses the development, testing and evolution of technology for such purposes. Our goals involve the development of mass spectrometry for the analysis of protein structure, assembly and dynamics, but we realize that this powerful technology will be insufficient for generating the degree of resolution we need to understand function. Computational methods will be developed to enhance the value of the data generated by mass spectrometry. With the successful development and maturation of this "merged" approach, we hope initiate new projects in therapeutics development focused on cancer treatment.